Topiramate’s effectiveness on weight reduction in overweight/obese persons with Schizophrenia
Phase 4
- Conditions
- Schizophrenia, Obesity, Overweight
- Registration Number
- SLCTR/2017/003
- Lead Sponsor
- Department of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow up complete
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
1. Diagnosis of schizophrenia (International Classification of Diseases (ICD), 10th edition)
2. Age 18 years and above
3. Capacity to give informed consent (as determined by assessment of an external psychiatrist)
4. Body Mass Index above the cut-off for Asians, which is 23 kg/m2 by the World Health Organization
Exclusion Criteria
1. Diabetes mellitus
2. Hypertension
3. Dyslipidaemia
4. Patients on other weight reducing agents
5. Patients with a significant loss of appetite leading to loss of more than 10% of body weight over a period of six months
6. Patients with difficulty in swallowing
7. Pregnant and lactating females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in body weight<br> [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]<br>Reduction in waist circumference<br> [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]<br>Reduction in skin fold thickness<br> [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]<br>
- Secondary Outcome Measures
Name Time Method A potential change in psychiatric symptoms as measured by the brief psychiatric rating scale (BPRS) [At base line and then every four weeks until the completion of 3 months from commencement of the intervention ]<br>